AbbVie SKYRIZI Met All Primary, Secondary Endpoints V. Stelara in Head-to-Head Study in Crohn's

 

• SEQUENCE, a Phase 3 head-to-head study (study drug open-label and efficacy assessment blinded) compared risankizumab to ustekinumab for the treatment of adult patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs¹
• Risankizumab met both primary endpoints of non-inferiority for clinical remission (Crohn's Disease Activity Index [CDAI]) at week 24 and superiority of endoscopic remission at week 48 versus ustekinumab
• All secondary endpoints achieved statistical significance for superiority versus ustekinumab
• Safety results were consistent with the overall safety profile of risankizumab, with no new safety risks identified

https://www.biospace.com/article/releases/abbvie-s-skyrizi-risankizumab-met-all-primary-and-secondary-endpoints-versus-stelara-ustekinumab-in-head-to-head-study-in-crohn-s-disease/